CD274 and inflammatory bowel disease: This safety problem of PD-L1-Fc limits its further use in IBD therapy; therefore, developing a method of targeted delivery of PD-L1-Fc to the inflamed area in IBD is a strategy to address the side effects of PD-L1-Fc.